Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator-led clinical study of NP-120 (Ifenprodil) for the treatment of COVID-19 infected patients with severe pneumonia

Next Previous
Trial Profile

An investigator-led clinical study of NP-120 (Ifenprodil) for the treatment of COVID-19 infected patients with severe pneumonia

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ifenprodil (Primary) ; Anti-inflammatories
  • Indications COVID 2019 infections; Pneumonia
  • Focus Adverse reactions; First in man

Most Recent Events

  • 13 Nov 2020 According to an Algernon Pharmaceuticals media release, the company will be providing an update on its Ifenprodil Phase 2 human clinical studies presented by Christopher J. Moreau, CEO and Dr. Mark Williams, CSO and hosted by Dr. KSS MD PhD. The BioPub webcast will be held on November 13, 2020
  • 09 Oct 2020 According to an Algernon Pharmaceuticals media release, due to a lack of sufficiently ill patients, which is a direct result of a highly-successful government initiated pandemic mitigation strategy, the company has decided to close this investigator-led trial. Instead, the company will remain focused on its Phase 2b/3 multinational Ifenprodil COVID study.
  • 09 Oct 2020 Status changed from planning to withdrawn prior to enrolment, according to an Algernon Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top